135 related articles for article (PubMed ID: 38335967)
21. Tumour cell retention of rucaparib, sustained PARP inhibition and efficacy of weekly as well as daily schedules.
Murray J; Thomas H; Berry P; Kyle S; Patterson M; Jones C; Los G; Hostomsky Z; Plummer ER; Boddy AV; Curtin NJ
Br J Cancer; 2014 Apr; 110(8):1977-84. PubMed ID: 24556618
[TBL] [Abstract][Full Text] [Related]
22. Imaging PARP with [
Chan CY; Chen Z; Destro G; Veal M; Lau D; O'Neill E; Dias G; Mosley M; Kersemans V; Guibbal F; Gouverneur V; Cornelissen B
Eur J Nucl Med Mol Imaging; 2022 Sep; 49(11):3668-3678. PubMed ID: 35614267
[TBL] [Abstract][Full Text] [Related]
23. An evaluation in vitro of PARP-1 inhibitors, rucaparib and olaparib, as radiosensitisers for the treatment of neuroblastoma.
Nile DL; Rae C; Hyndman IJ; Gaze MN; Mairs RJ
BMC Cancer; 2016 Aug; 16():621. PubMed ID: 27515310
[TBL] [Abstract][Full Text] [Related]
24. How safe is rucaparib in ovarian cancer?
Cosgrove CM; O'Malley DM
Expert Opin Drug Saf; 2018 Dec; 17(12):1249-1255. PubMed ID: 30449210
[No Abstract] [Full Text] [Related]
25. Real-World Delivery of Rucaparib to Patients with Ovarian Cancer: Recommendations Based on an Integrated Safety Analysis of ARIEL2 and Study 10.
Drew Y; Kristeleit RS; Oaknin A; Ray-Coquard I; Haris NM; Swisher EM
Oncologist; 2020 Jan; 25(1):e109-e119. PubMed ID: 31575788
[TBL] [Abstract][Full Text] [Related]
26. The growing role of rucaparib in contemporary treatment of metastatic prostate cancer: a review of efficacy and guidance for side effect management.
Rao A; Antonarakis ES
Expert Rev Anticancer Ther; 2022 Jul; 22(7):671-679. PubMed ID: 35594523
[TBL] [Abstract][Full Text] [Related]
27. PARP1-siRNA suppresses human prostate cancer cell growth and progression.
Lai Y; Kong Z; Zeng T; Xu S; Duan X; Li S; Cai C; Zhao Z; Wu W
Oncol Rep; 2018 Apr; 39(4):1901-1909. PubMed ID: 29393407
[TBL] [Abstract][Full Text] [Related]
28. Vasoactivity of rucaparib, a PARP-1 inhibitor, is a complex process that involves myosin light chain kinase, P2 receptors, and PARP itself.
McCrudden CM; O'Rourke MG; Cherry KE; Yuen HF; O'Rourke D; Babur M; Telfer BA; Thomas HD; Keane P; Nambirajan T; Hagan C; O'Sullivan JM; Shaw C; Williams KJ; Curtin NJ; Hirst DG; Robson T
PLoS One; 2015; 10(2):e0118187. PubMed ID: 25689628
[TBL] [Abstract][Full Text] [Related]
29. Activity of trabectedin and the PARP inhibitor rucaparib in soft-tissue sarcomas.
Laroche A; Chaire V; Le Loarer F; Algéo MP; Rey C; Tran K; Lucchesi C; Italiano A
J Hematol Oncol; 2017 Apr; 10(1):84. PubMed ID: 28399901
[TBL] [Abstract][Full Text] [Related]
30. PARP inhibitors in prostate cancer: time to narrow patient selection?
Markowski MC; Antonarakis ES
Expert Rev Anticancer Ther; 2020 Jul; 20(7):523-526. PubMed ID: 32521178
[No Abstract] [Full Text] [Related]
31. Proteomic Analysis Reveals Low-Dose PARP Inhibitor-Induced Differential Protein Expression in BRCA1-Mutated High-Grade Serous Ovarian Cancer Cells.
Perez JM; Twigg CAI; Guan W; Thomas SN
J Am Soc Mass Spectrom; 2022 Feb; 33(2):242-250. PubMed ID: 34958553
[TBL] [Abstract][Full Text] [Related]
32. Pharmacokinetics and safety of rucaparib in patients with advanced solid tumors and hepatic impairment.
Grechko N; Skarbova V; Tomaszewska-Kiecana M; Ramlau R; Centkowski P; Drew Y; Dziadziuszko R; Zemanova M; Beltman J; Nash E; Habeck J; Liao M; Xiao J
Cancer Chemother Pharmacol; 2021 Aug; 88(2):259-270. PubMed ID: 33909097
[TBL] [Abstract][Full Text] [Related]
33. PARP inhibitor cyanine dye conjugate with enhanced cytotoxic and antiproliferative activity in patient derived glioblastoma cell lines.
Choi PJ; Cooper E; Schweder P; Mee E; Turner C; Faull R; Denny WA; Dragunow M; Park TI; Jose J
Bioorg Med Chem Lett; 2020 Jul; 30(14):127252. PubMed ID: 32527552
[TBL] [Abstract][Full Text] [Related]
34. Targeting the MYCN-PARP-DNA Damage Response Pathway in Neuroendocrine Prostate Cancer.
Zhang W; Liu B; Wu W; Li L; Broom BM; Basourakos SP; Korentzelos D; Luan Y; Wang J; Yang G; Park S; Azad AK; Cao X; Kim J; Corn PG; Logothetis CJ; Aparicio AM; Chinnaiyan AM; Navone N; Troncoso P; Thompson TC
Clin Cancer Res; 2018 Feb; 24(3):696-707. PubMed ID: 29138344
[No Abstract] [Full Text] [Related]
35. Poly(adenosine diphosphate ribose) polymerase inhibitors induce autophagy-mediated drug resistance in ovarian cancer cells, xenografts, and patient-derived xenograft models.
Santiago-O'Farrill JM; Weroha SJ; Hou X; Oberg AL; Heinzen EP; Maurer MJ; Pang L; Rask P; Amaravadi RK; Becker SE; Romero I; Rubio MJ; Matias-Guiu X; Santacana M; Llombart-Cussac A; Poveda A; Lu Z; Bast RC
Cancer; 2020 Feb; 126(4):894-907. PubMed ID: 31714594
[TBL] [Abstract][Full Text] [Related]
36. Attenuation of Tumor Burden in Response to Rucaparib in Lung Adenocarcinoma: The Contribution of Oxidative Stress, Apoptosis, and DNA Damage.
Pérez-Peiró M; Valentí-Serra P; León-González B; Ampurdanés C; Duran X; Yélamos J; Barreiro E
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768904
[TBL] [Abstract][Full Text] [Related]
37. Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer.
Drew Y; Ledermann J; Hall G; Rea D; Glasspool R; Highley M; Jayson G; Sludden J; Murray J; Jamieson D; Halford S; Acton G; Backholer Z; Mangano R; Boddy A; Curtin N; Plummer R
Br J Cancer; 2016 Mar; 114(7):723-30. PubMed ID: 27002934
[TBL] [Abstract][Full Text] [Related]
38. Efficacy of PARP Inhibitor Rucaparib in Orthotopic Glioblastoma Xenografts Is Limited by Ineffective Drug Penetration into the Central Nervous System.
Parrish KE; Cen L; Murray J; Calligaris D; Kizilbash S; Mittapalli RK; Carlson BL; Schroeder MA; Sludden J; Boddy AV; Agar NY; Curtin NJ; Elmquist WF; Sarkaria JN
Mol Cancer Ther; 2015 Dec; 14(12):2735-43. PubMed ID: 26438157
[TBL] [Abstract][Full Text] [Related]
39. Poly(ADP-ribose) Polymerase in Neurodegeneration: Radiosynthesis and Radioligand Binding in ARC-SWE tg Mice.
Alluri SR; Riss PJ
ACS Chem Neurosci; 2018 Jun; 9(6):1259-1263. PubMed ID: 29544053
[TBL] [Abstract][Full Text] [Related]
40. The BET inhibitor INCB054329 reduces homologous recombination efficiency and augments PARP inhibitor activity in ovarian cancer.
Wilson AJ; Stubbs M; Liu P; Ruggeri B; Khabele D
Gynecol Oncol; 2018 Jun; 149(3):575-584. PubMed ID: 29567272
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
